Clinical trial
Study Evaluating MST-997 in Advanced Malignant Solid Tumors
NCT00277836 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00277836 |
|---|---|
| Title | Study Evaluating MST-997 in Advanced Malignant Solid Tumors |
| Official title | A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Polysorbate 80 Diluent Administered Weekly in Subjects With Advanced Malignant Solid Tumors |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | MST-997 |
| Enrollment | 60 |
| First posted | Jan 16, 2006 |
| Last update posted | Dec 8, 2006 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: